Posted by Michael Wonder on 30 Nov 2023
FDA accepts Arcutis’ supplemental new drug application for roflumilast 0.15% cream for the treatment of atopic dermatitis in adults and children down to age 6
29 November 2023 - FDA has set a PDUFA target action date of 7 July 2024.
Arcutis Biotherapeutics today announced the US FDA has accepted its supplemental new drug application for roflumilast cream 0.15% for the treatment of atopic dermatitis in adults and children down to age 6.
